Atossa Genetics (ATOS)
(Real Time Quote from BATS)
$1.56 USD
+0.04 (2.63%)
Updated Apr 26, 2024 10:46 AM ET
3-Hold of 5 3
D Value C Growth D Momentum C VGM
Balance Sheet
Fiscal Year End for Atossa Genetics Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 89 | 111 | 136 | 40 | 13 |
Receivables | 0 | 1 | 1 | 1 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 4 | 6 | 4 | 2 | 1 |
Total Current Assets | 92 | 118 | 141 | 43 | 14 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 2 | 5 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 1 | 0 | 0 | 0 |
Total Assets | 96 | 124 | 141 | 43 | 14 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 3 | 2 | 2 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 1 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 2 | 1 | 14 | 1 |
Total Current Liabilities | 5 | 6 | 3 | 16 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5 | 6 | 3 | 16 | 1 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 1 | 1 | 1 | 1 |
Common Stock (Par) | 23 | 23 | 23 | 9 | 2 |
Capital Surplus | 256 | 251 | 244 | 130 | 105 |
Retained Earnings | -186 | -156 | -129 | -112 | -94 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 1 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 91 | 118 | 138 | 27 | 13 |
Total Liabilities & Shareholder's Equity | 96 | 124 | 141 | 43 | 14 |
Total Common Equity | 91 | 117 | 138 | 27 | 12 |
Shares Outstanding | 125.30 | 126.60 | 126.60 | 71.50 | 9.10 |
Book Value Per Share | 0.73 | 0.93 | 1.09 | 0.37 | 1.37 |
Fiscal Year End for Atossa Genetics Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 89 | 94 | 100 | 104 |
Receivables | NA | 0 | 0 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 4 | 3 | 6 | 6 |
Total Current Assets | NA | 92 | 98 | 106 | 111 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 2 | 2 | 2 | 5 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 2 | 2 | 1 | 1 |
Total Assets | NA | 96 | 102 | 108 | 116 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 1 | 1 | 1 | 1 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 3 | 1 | 2 | 1 |
Total Current Liabilities | NA | 5 | 3 | 3 | 3 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 5 | 3 | 3 | 3 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 1 | 1 | 1 |
Common Stock (Par) | NA | 23 | 23 | 23 | 23 |
Capital Surplus | NA | 256 | 255 | 254 | 252 |
Retained Earnings | NA | -186 | -179 | -172 | -162 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 1 | 1 | 0 | 0 |
Total Shareholder's Equity | NA | 91 | 98 | 105 | 113 |
Total Liabilities & Shareholder's Equity | NA | 96 | 102 | 108 | 116 |
Total Common Equity | 0 | 91 | 98 | 104 | 113 |
Shares Outstanding | 125.30 | 125.30 | 125.70 | 126.60 | 126.70 |
Book Value Per Share | 0.00 | 0.73 | 0.78 | 0.82 | 0.89 |